43 related articles for article (PubMed ID: 35944353)
1. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
[TBL] [Abstract][Full Text] [Related]
2. Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.
Bueno MJ; Mouron S; Caleiras E; Martínez M; Manso L; Colomer R; Quintela-Fandino M
Clin Transl Oncol; 2024 May; 26(5):1273-1279. PubMed ID: 37851244
[TBL] [Abstract][Full Text] [Related]
3. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
4. The role of taxanes in triple-negative breast cancer: literature review.
Mustacchi G; De Laurentiis M
Drug Des Devel Ther; 2015; 9():4303-18. PubMed ID: 26273192
[TBL] [Abstract][Full Text] [Related]
5. Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
Kitsuya N; Matsuoka M; Onodera T; Yokota I; Iwasaki K; Suzuki Y; Hamasaki M; Kondo E; Iwasaki N
Anticancer Res; 2024 Apr; 44(4):1591-1601. PubMed ID: 38537990
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in the treatment of HER2-negative breast cancer.
Lorusso V
Biologics; 2008 Dec; 2(4):813-21. PubMed ID: 19707460
[TBL] [Abstract][Full Text] [Related]
7. Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane-PLD versus PLD-Taxane in Patients with Metastatic Breast Cancer.
Wallrabenstein T; Oseledchyk A; Daetwyler E; Rochlitz C; Vetter M
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894320
[No Abstract] [Full Text] [Related]
8. Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
Id Said B; Soliman H; Moravan V; Myrehaug S; Tseng CL; Detsky J; Sahgal A; Warner E; Jerzak KJ
J Neurooncol; 2023 Sep; 164(2):437-445. PubMed ID: 37634217
[TBL] [Abstract][Full Text] [Related]
9. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Bertho M; Fraisse J; Patsouris A; Cottu P; Arnedos M; Pérol D; Jaffré A; Goncalves A; Lebitasy MP; D'Hondt V; Dalenc F; Ferrero JM; Levy C; Dabakuyo S; Rouzier R; Penault-Llorca F; Uwer L; Eymard JC; Breton M; Chevrot M; Thureau S; Petit T; Simon G; Frénel JS
Ther Adv Med Oncol; 2021; 13():1758835920987657. PubMed ID: 33613700
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Cazzaniga ME; Pronzato P; Amoroso D; Bernardo A; Biganzoli L; Bisagni G; Blasi L; Bria E; Cognetti F; Crinò L; De Laurentiis M; Del Mastro L; De Placido S; Beano A; Ferraù F; Foladore S; Forcignanò R; Gamucci T; Garrone O; Gennari A; Giordano M; Giotta F; Giovanardi F; Latini L; Livi L; Marchetti P; Mattioli R; Michelotti A; Montemurro F; Putzu C; Riccardi F; Ricciardi G; Romagnoli E; Sarobba G; Spazzapan S; Tagliaferri P; Tinari N; Tonini G; Turletti A; Verusio C; Zambelli A; Mustacchi G
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201545
[TBL] [Abstract][Full Text] [Related]
11. Updates in the treatment of HR+HER2- breast cancer.
Baclig NV; McCann KE
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):57-63. PubMed ID: 38170552
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Recurrent Breast Cancer with Delayed Wound Healing Induced by Bevacizumab].
Terasawa R; Hirata A; Aoki C; Kimura K; Morita S; Hayashi M
Gan To Kagaku Ryoho; 2024 Mar; 51(3):287-289. PubMed ID: 38494810
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and taxanes in metastatic breast cancer: a systematic review.
Gudena V; Montero AJ; Glück S
Ther Clin Risk Manag; 2008 Dec; 4(6):1157-64. PubMed ID: 19337423
[TBL] [Abstract][Full Text] [Related]
14. Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report.
Gluz O; Kolberg-Liedtke C; Marmé F; Thill M
Geburtshilfe Frauenheilkd; 2020 Apr; 80(4):399-409. PubMed ID: 32322109
[TBL] [Abstract][Full Text] [Related]
15. Unexpected "Lazarus response" to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer.
Emshanov AV; Nesterov DV; Sokolova TN; Amankwah PS; Imyanitov EN
Explor Target Antitumor Ther; 2023; 4(6):1157-1164. PubMed ID: 38213542
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
Liu S; Zhi W; Zhang L
J Cell Mol Med; 2023 Oct; 28(5):e18008. PubMed ID: 37891706
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.
Vasseur A; Carton M; Guiu S; Augereau P; Uwer L; Mouret-Reynier MA; Levy C; Eymard JC; Ferrero JM; Leheurteur M; Goncalves A; Robert M; De La Motte Rouge T; Bachelot T; Petit T; Debled M; Grinda T; Desmoulins I; Vanlemmens L; Nicolaï V; Simon G; Cabel L
Breast; 2022 Oct; 65():136-144. PubMed ID: 35944353
[TBL] [Abstract][Full Text] [Related]
18. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Réda M; Fouquier A; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Coudert B; Bertaut A; Ladoire S
Breast; 2023 Apr; 68():149-156. PubMed ID: 36773403
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
Chan A; Miles DW; Pivot X
Ann Oncol; 2010 Dec; 21(12):2305-2315. PubMed ID: 20335367
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
